Review
. 2018 Jul; 16(1):144.
doi: 10.1186/s12957-018-1424-4.

Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials

Wenqi Zhou 1 Shizhe Chen 2 Faliang Xu 1 Xiaohua Zeng 3 
Affiliations
  • PMID: 30007402
  •     24 References
  •     3 citations

Abstract

Background: Dose-dense chemotherapy is a widely accepted regimen for high-risk breast cancer patients. However, conflicting survival benefits of pure dose-dense chemotherapy have been reported in different randomized controlled trials (RCTs). This meta-analysis aimed to further assess the efficacy and safety of pure dose-dense chemotherapy in breast cancer.

Methods: A literature search of electronic databases and websites was performed to identify phase III RCTs reporting the efficacy and toxicity of pure dose-dense chemotherapy. The endpoints of interest were overall survival (OS), disease-free survival (DFS), and toxicities. The hazard ratios (HRs) of death and recurrence and the odds ratios (ORs) of adverse events were estimated and pooled.

Results: Seven studies (five trials) were eligible, encompassing a total of 9851 patients. Patients treated with dose-dense chemotherapy obtained better DFS (HR = 0.83; 95% CI 0.75-0.91; p = 0.0001) than those treated with the conventional schedule, while OS benefit of dose-dense chemotherapy was less impressive (HR = 0.86; 95% CI 0.73-1.02; p = 0.08). However, significant OS benefit was observed in node-positive patients (HR = 0.77; 95% CI 0.66-0.90; p = 0.001). The incidence of anemia, pain, and transaminase elevation was higher in the dose-dense chemotherapy arm.

Conclusions: Dose-dense chemotherapy leads to better prognosis; these findings suggest that it may be a potentially preferred treatment for breast cancer patients, particularly for women with lymph node involvement. However, more RCTs are warranted to better define the best candidates for dose-dense chemotherapy.

Keywords: Breast cancer; Chemotherapy; Dose-dense; Meta-analysis; Overall survival.

Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias.
Karsten Knobloch, Uzung Yoon, Peter M Vogt.
J Craniomaxillofac Surg, 2010 Dec 15; 39(2). PMID: 21145753
Highly Cited.
St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.
Michael Gnant, Nadia Harbeck, Christoph Thomssen.
Breast Care (Basel), 2017 Jun 01; 12(2). PMID: 28559767    Free PMC article.
Highly Cited. Review.
Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.
Igor Lemos Duarte, João Paulo da Silveira Nogueira Lima, Carmen Silvia Passos Lima, André Deeke Sasse.
Breast, 2012 Mar 20; 21(3). PMID: 22425607
Systematic Review.
Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data.
Heather L McArthur, Clifford A Hudis.
Clin Breast Cancer, 2008 Feb 20; 8 Suppl 1. PMID: 18282369
Review.
Practical methods for incorporating summary time-to-event data into meta-analysis.
Jayne F Tierney, Lesley A Stewart, +2 authors, Matthew R Sydes.
Trials, 2007 Jun 09; 8. PMID: 17555582    Free PMC article.
Highly Cited.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
A Gompertzian model of human breast cancer growth.
L Norton.
Cancer Res, 1988 Dec 15; 48(24 Pt 1). PMID: 3191483
Highly Cited.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
David Cameron, James P Morden, +22 authors, TACT2 Investigators.
Lancet Oncol, 2017 Jun 11; 18(7). PMID: 28600210    Free PMC article.
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
M K Parmar, V Torri, L Stewart.
Stat Med, 1999 Jan 28; 17(24). PMID: 9921604
Highly Cited.
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
Neelima Denduluri, Mark R Somerfield, +8 authors, Antonio C Wolff.
J Clin Oncol, 2016 Apr 20; 34(20). PMID: 27091714
Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2017 Jan 06; 67(1). PMID: 28055103
Highly Cited.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Lucia Del Mastro, Sabino De Placido, +22 authors, Gruppo Italiano Mammella (GIM) investigators.
Lancet, 2015 Mar 06; 385(9980). PMID: 25740286
The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.
Richard Simon, Larry Norton.
Nat Clin Pract Oncol, 2006 Aug 09; 3(8). PMID: 16894366
Review.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
E Baldini, G Gardin, +9 authors, P F Conte.
Ann Oncol, 2003 Feb 04; 14(2). PMID: 12562649
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Matteo Lambertini, Marcello Ceppi, +20 authors, MIG and GIM study groups.
Eur J Cancer, 2016 Dec 13; 71. PMID: 27951450
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Marco Venturini, Lucia Del Mastro, +11 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2005 Dec 08; 97(23). PMID: 16333028
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
George T Budd, William E Barlow, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2014 Nov 26; 33(1). PMID: 25422488    Free PMC article.
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Joseph A Sparano, Fengmin Zhao, +7 authors, Nancy E Davidson.
J Clin Oncol, 2015 Jun 17; 33(21). PMID: 26077235    Free PMC article.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Bias in meta-analysis detected by a simple, graphical test.
M Egger, G Davey Smith, M Schneider, C Minder.
BMJ, 1997 Oct 06; 315(7109). PMID: 9310563    Free PMC article.
Highly Cited.
Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.
Fausto Petrelli, Mary Cabiddu, +4 authors, Sandro Barni.
Breast Cancer Res Treat, 2015 Apr 29; 151(2). PMID: 25917869
Systematic Review.
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Volker Moebus, Christian Jackisch, +14 authors, Michael Untch.
J Clin Oncol, 2010 May 12; 28(17). PMID: 20458045
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, +9 authors, Cochrane Statistical Methods Group.
BMJ, 2011 Oct 20; 343. PMID: 22008217    Free PMC article.
Highly Cited.
Granulocyte Colony Stimulating Factor (G-CSF) Induced Splenic Infarction in Breast Cancer Patient Treated with Dose-Dense Chemotherapy Regimen.
Majed A Alshamrani, Meteb Al-Foheidi, Ahmed H Abdulrahim.
Case Rep Oncol Med, 2019 Mar 25; 2019. PMID: 30906610    Free PMC article.
Breast cancer: insights in disease and influence of drug methotrexate.
Vítor Yang, Maria João Gouveia, +4 authors, Nuno Vale.
RSC Med Chem, 2021 Jan 23; 11(6). PMID: 33479665    Free PMC article.
Review.
Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer.
Dorel Popovici, Cristina Oprean, +6 authors, Șerban Negru.
Exp Ther Med, 2021 Jun 01; 22(1). PMID: 34055062    Free PMC article.